Avaliação dos marcadores celulares por citometria de fluxo nos portadores de leucemia mieloide aguda atendidos no Hemocentro do Rio Grande do Norte-Hemonorte

Detalhes bibliográficos
Ano de defesa: 2010
Autor(a) principal: Vasconcelos, Roberto Chaves de
Orientador(a): Não Informado pela instituição
Banca de defesa: Não Informado pela instituição
Tipo de documento: Dissertação
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Universidade Federal do Rio Grande do Norte
Programa de Pós-Graduação: Programa de Pós-Graduação em Ciências Farmacêuticas
Departamento: Bioanálises e Medicamentos
País: BR
Palavras-chave em Português:
Palavras-chave em Inglês:
Área do conhecimento CNPq:
Link de acesso: https://repositorio.ufrn.br/jspui/handle/123456789/13464
Resumo: The acute myeloid leukemia (AML) is a disease in which malignant myeloblasts expand, build up and suppress normal hematopoietic activity would represent a major diagnostic challenge. With the advent of immunophenotyping by flow cytometry, the diagnosis of these tumors have become more faithful, facilitating the treatment and monitoring of patients. The objectives of this study: diagnosis and classification of AML based on immunophenotyping by flow cytometry with a panel of AcMo specific for acute leukemias, set the frequency of AML in samples from patients with acute leukemias sent to the Department of Hematology Blood Center of Rio Grande do Norte - HEMONORTE, establish standards of antigen expression for different subtypes of acute leukemia and its correlation with the newly diagnosed cases refractory to treatment and recurrence of the disease, standardization of methods for detection and labeling of surface antigens by flow cytometry and intracytoplasmic flow, and observe the frequency of acute leukemia with aberrant phenotypes rare. During the study, 351 were diagnosed acute leukemia, and 179 (51%) classified as AML and 172 (49%) and ALL, which were excluded from the present work. Of the 179 AML, 92 (51.4%) were female and 87 (48.6%) were male, with ages ranging from 3 to 95 years of ag, with higher incidence in individuals in the age group of 41 to 65. Splenomegaly was the clinical finding more present, a total of 147 cases (82.1%), followed by hepatomegaly present in 132 cases (73.7%). The hemorrhagic events were observed in 55 cases (30.7%). Lymphadenopathy in turn was detected in 20 of 179 cases (11.2%). In order to classify subtypes of AML, we used a large panel of monoclonal antibodies, obtaining the following results: AML M0, 02 (1.1%) AML M1, 40 (22.3) AML M2, 60 (33.5) AML M3, 22 (12.3%) AML M4, 10 (5.6) AML M5, 13 (7.3%) AML M6 06 (3.4%) and AML M7 01 (0.6%). We observed some cases with aberrant expression of some antigens such as CD7, CD4, CD19, CD3, CD5 and TdT, CD 7 was present in 30 (16.8%), CD4 in 5 (2.8%), the CD 3 in 5 (2.8%), the CD19 in 3 (1.7%), the CD5 in 3 (1.7%) and TDT was in 7 (3.9%) cases of AML .the CD8 and CD79a was present in only a 1 case.
id UFRN_62fb50f864272ced9ce66adf1ba83287
oai_identifier_str oai:https://repositorio.ufrn.br:123456789/13464
network_acronym_str UFRN
network_name_str Repositório Institucional da UFRN
repository_id_str
spelling Vasconcelos, Roberto Chaves dehttp://lattes.cnpq.br/7417816577967890http://lattes.cnpq.br/0091662650633339Freire, Flávio Henrique Miranda de Araújohttp://lattes.cnpq.br/7623751650258443Alves, Carlos Roberto2014-12-17T14:16:28Z2012-05-212014-12-17T14:16:28Z2010-02-24VASCONCELOS, Roberto Chaves de. Avaliação dos marcadores celulares por citometria de fluxo nos portadores de leucemia mieloide aguda atendidos no Hemocentro do Rio Grande do Norte-Hemonorte. 2010. 121 f. Dissertação (Mestrado em Bioanálises e Medicamentos) - Universidade Federal do Rio Grande do Norte, Natal, 2010.https://repositorio.ufrn.br/jspui/handle/123456789/13464The acute myeloid leukemia (AML) is a disease in which malignant myeloblasts expand, build up and suppress normal hematopoietic activity would represent a major diagnostic challenge. With the advent of immunophenotyping by flow cytometry, the diagnosis of these tumors have become more faithful, facilitating the treatment and monitoring of patients. The objectives of this study: diagnosis and classification of AML based on immunophenotyping by flow cytometry with a panel of AcMo specific for acute leukemias, set the frequency of AML in samples from patients with acute leukemias sent to the Department of Hematology Blood Center of Rio Grande do Norte - HEMONORTE, establish standards of antigen expression for different subtypes of acute leukemia and its correlation with the newly diagnosed cases refractory to treatment and recurrence of the disease, standardization of methods for detection and labeling of surface antigens by flow cytometry and intracytoplasmic flow, and observe the frequency of acute leukemia with aberrant phenotypes rare. During the study, 351 were diagnosed acute leukemia, and 179 (51%) classified as AML and 172 (49%) and ALL, which were excluded from the present work. Of the 179 AML, 92 (51.4%) were female and 87 (48.6%) were male, with ages ranging from 3 to 95 years of ag, with higher incidence in individuals in the age group of 41 to 65. Splenomegaly was the clinical finding more present, a total of 147 cases (82.1%), followed by hepatomegaly present in 132 cases (73.7%). The hemorrhagic events were observed in 55 cases (30.7%). Lymphadenopathy in turn was detected in 20 of 179 cases (11.2%). In order to classify subtypes of AML, we used a large panel of monoclonal antibodies, obtaining the following results: AML M0, 02 (1.1%) AML M1, 40 (22.3) AML M2, 60 (33.5) AML M3, 22 (12.3%) AML M4, 10 (5.6) AML M5, 13 (7.3%) AML M6 06 (3.4%) and AML M7 01 (0.6%). We observed some cases with aberrant expression of some antigens such as CD7, CD4, CD19, CD3, CD5 and TdT, CD 7 was present in 30 (16.8%), CD4 in 5 (2.8%), the CD 3 in 5 (2.8%), the CD19 in 3 (1.7%), the CD5 in 3 (1.7%) and TDT was in 7 (3.9%) cases of AML .the CD8 and CD79a was present in only a 1 case.A Leucemia Mielóide Aguda (LMA) é uma doença maligna em que os mieloblastos expandem-se, acumulam-se e suprimem a atividade hematopoética normal, constituindo um grande desafio diagnóstico. Com o advento da imunofenotipagem por citometria de fluxo, o diagnóstico dessas neoplasias se tornaram mais fiéis, facilitando o tratamento e o acompanhamento dos pacientes. Foram objetivos deste estudo: diagnosticar e classificar as LMA com base na imunofenotipagem por citometria de fluxo, com um painel de AcMo específico para leucemias agudas; estabelecer a frequência de LMA nas amostras de pacientes com leucemias agudas encaminhadas ao Departamento de Hematologia do Hemocentro do Rio Grande do Norte HEMONORTE; estabelecer padrões de expressão antigênica para os diversos subtipos de leucemias agudas e a sua correlação com os casos recém diagnosticados, refratários ao tratamento e recorrência da doença; padronização dos métodos de detecção e marcação de antígenos de superfície e intracitoplasmático por citometria de fluxo; e observar a freqüência de leucemias agudas com fenótipos aberrantes raros. Durante o estudo, foram diagnosticados 351 leucemias agudas, sendo 179 (51%) classificadas como LMA e 172 (49%) como LLA, as quais foram excluídas do presente trabalho. Das 179 LMA, 92 (51,4%) eram do sexo feminino e 87 (48,6%) do sexo masculino, com faixa etária variando de 3 a 95 anos de idade, com maior incidência em indivíduos na faixa etária de 41 a 65 anos. A esplenomegalia foi o achado clínico mais presente, perfazendo um total de 147 casos (82,1%), seguida da hepatomegalia presente em 132 casos (73,7%). Os fenômenos hemorragicos foram observado em 55 casos ( 30,7%). A linfoadenopatia por sua vez foi constatada em 20 dos 179 casos (11,2%). Para classificação dos subtipos de LMA foi utilizado um painel amplo de anticorpos monoclonais, obtendo os seguintes resultados: LMA M0, 02 (1.1%) LMA M1, 40 (22.3) LMA M2, 60 (33.5) LMA M3, 22 (12.3%) LMA M4, 10 (5.6) LMA M5, 13 (7.3%) LMA M6 06 (3.4%) e LMA M7 01 (0.6%). Foram observados alguns casos com expressão aberrante de alguns antígenos tais como CD7, CD4, CD19, CD3, CD5 e TdT, O CD7 esteve presente em 30 (16,8%) , o CD4 em 5 (2,8%), o CD 3 em 5 (2,8%), o CD19 em 3 (1,7%), o CD5 em 3 (1,7%) e o TDT esteve em 7 (3,9%) casos de LMA diagnosticados.O CD8 e o CD79a esteve presente em apenas um 1 caso.Coordenação de Aperfeiçoamento de Pessoal de Nível Superiorapplication/pdfporUniversidade Federal do Rio Grande do NortePrograma de Pós-Graduação em Ciências FarmacêuticasUFRNBRBioanálises e MedicamentosCitometria de fluxoImunofenotipagemLeucemia mielóide aguda.Flow cytometryImmunophenotypingAcute myeloid leukemia.CNPQ::CIENCIAS DA SAUDE::FARMACIAAvaliação dos marcadores celulares por citometria de fluxo nos portadores de leucemia mieloide aguda atendidos no Hemocentro do Rio Grande do Norte-Hemonorteinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRNinstname:Universidade Federal do Rio Grande do Norte (UFRN)instacron:UFRNORIGINALAvaliacaoMarcadoresCelulares_Vasconcelos_2010.pdfapplication/pdf2201581https://repositorio.ufrn.br/bitstream/123456789/13464/1/AvaliacaoMarcadoresCelulares_Vasconcelos_2010.pdfa5ed04f6ae5794f328192fe513bdf03fMD51TEXTRobertoCV_DISSERT.pdf.txtRobertoCV_DISSERT.pdf.txtExtracted texttext/plain174768https://repositorio.ufrn.br/bitstream/123456789/13464/6/RobertoCV_DISSERT.pdf.txteb75e5e0b0b579d56e81d3bf30484dc7MD56AvaliacaoMarcadoresCelulares_Vasconcelos_2010.pdf.txtAvaliacaoMarcadoresCelulares_Vasconcelos_2010.pdf.txtExtracted texttext/plain174740https://repositorio.ufrn.br/bitstream/123456789/13464/8/AvaliacaoMarcadoresCelulares_Vasconcelos_2010.pdf.txtac68c063005584c312af018ad008b4e4MD58THUMBNAILRobertoCV_DISSERT.pdf.jpgRobertoCV_DISSERT.pdf.jpgIM Thumbnailimage/jpeg3299https://repositorio.ufrn.br/bitstream/123456789/13464/7/RobertoCV_DISSERT.pdf.jpg2e1e190227428bd5c170cab067e82d11MD57AvaliacaoMarcadoresCelulares_Vasconcelos_2010.pdf.jpgAvaliacaoMarcadoresCelulares_Vasconcelos_2010.pdf.jpgGenerated Thumbnailimage/jpeg1342https://repositorio.ufrn.br/bitstream/123456789/13464/9/AvaliacaoMarcadoresCelulares_Vasconcelos_2010.pdf.jpg749abb9c20f803dc5218c4df1072179bMD59123456789/134642019-05-26 02:22:03.488oai:https://repositorio.ufrn.br:123456789/13464Repositório de PublicaçõesPUBhttp://repositorio.ufrn.br/oai/opendoar:2019-05-26T05:22:03Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN)false
dc.title.por.fl_str_mv Avaliação dos marcadores celulares por citometria de fluxo nos portadores de leucemia mieloide aguda atendidos no Hemocentro do Rio Grande do Norte-Hemonorte
title Avaliação dos marcadores celulares por citometria de fluxo nos portadores de leucemia mieloide aguda atendidos no Hemocentro do Rio Grande do Norte-Hemonorte
spellingShingle Avaliação dos marcadores celulares por citometria de fluxo nos portadores de leucemia mieloide aguda atendidos no Hemocentro do Rio Grande do Norte-Hemonorte
Vasconcelos, Roberto Chaves de
Citometria de fluxo
Imunofenotipagem
Leucemia mielóide aguda.
Flow cytometry
Immunophenotyping
Acute myeloid leukemia.
CNPQ::CIENCIAS DA SAUDE::FARMACIA
title_short Avaliação dos marcadores celulares por citometria de fluxo nos portadores de leucemia mieloide aguda atendidos no Hemocentro do Rio Grande do Norte-Hemonorte
title_full Avaliação dos marcadores celulares por citometria de fluxo nos portadores de leucemia mieloide aguda atendidos no Hemocentro do Rio Grande do Norte-Hemonorte
title_fullStr Avaliação dos marcadores celulares por citometria de fluxo nos portadores de leucemia mieloide aguda atendidos no Hemocentro do Rio Grande do Norte-Hemonorte
title_full_unstemmed Avaliação dos marcadores celulares por citometria de fluxo nos portadores de leucemia mieloide aguda atendidos no Hemocentro do Rio Grande do Norte-Hemonorte
title_sort Avaliação dos marcadores celulares por citometria de fluxo nos portadores de leucemia mieloide aguda atendidos no Hemocentro do Rio Grande do Norte-Hemonorte
author Vasconcelos, Roberto Chaves de
author_facet Vasconcelos, Roberto Chaves de
author_role author
dc.contributor.authorID.por.fl_str_mv
dc.contributor.authorLattes.por.fl_str_mv http://lattes.cnpq.br/7417816577967890
dc.contributor.advisorID.por.fl_str_mv
dc.contributor.advisorLattes.por.fl_str_mv http://lattes.cnpq.br/0091662650633339
dc.contributor.referees1.pt_BR.fl_str_mv Freire, Flávio Henrique Miranda de Araújo
dc.contributor.referees1ID.por.fl_str_mv
dc.contributor.referees1Lattes.por.fl_str_mv http://lattes.cnpq.br/7623751650258443
dc.contributor.referees2.pt_BR.fl_str_mv Alves, Carlos Roberto
dc.contributor.referees2ID.por.fl_str_mv
dc.contributor.author.fl_str_mv Vasconcelos, Roberto Chaves de
dc.subject.por.fl_str_mv Citometria de fluxo
Imunofenotipagem
Leucemia mielóide aguda.
topic Citometria de fluxo
Imunofenotipagem
Leucemia mielóide aguda.
Flow cytometry
Immunophenotyping
Acute myeloid leukemia.
CNPQ::CIENCIAS DA SAUDE::FARMACIA
dc.subject.eng.fl_str_mv Flow cytometry
Immunophenotyping
Acute myeloid leukemia.
dc.subject.cnpq.fl_str_mv CNPQ::CIENCIAS DA SAUDE::FARMACIA
description The acute myeloid leukemia (AML) is a disease in which malignant myeloblasts expand, build up and suppress normal hematopoietic activity would represent a major diagnostic challenge. With the advent of immunophenotyping by flow cytometry, the diagnosis of these tumors have become more faithful, facilitating the treatment and monitoring of patients. The objectives of this study: diagnosis and classification of AML based on immunophenotyping by flow cytometry with a panel of AcMo specific for acute leukemias, set the frequency of AML in samples from patients with acute leukemias sent to the Department of Hematology Blood Center of Rio Grande do Norte - HEMONORTE, establish standards of antigen expression for different subtypes of acute leukemia and its correlation with the newly diagnosed cases refractory to treatment and recurrence of the disease, standardization of methods for detection and labeling of surface antigens by flow cytometry and intracytoplasmic flow, and observe the frequency of acute leukemia with aberrant phenotypes rare. During the study, 351 were diagnosed acute leukemia, and 179 (51%) classified as AML and 172 (49%) and ALL, which were excluded from the present work. Of the 179 AML, 92 (51.4%) were female and 87 (48.6%) were male, with ages ranging from 3 to 95 years of ag, with higher incidence in individuals in the age group of 41 to 65. Splenomegaly was the clinical finding more present, a total of 147 cases (82.1%), followed by hepatomegaly present in 132 cases (73.7%). The hemorrhagic events were observed in 55 cases (30.7%). Lymphadenopathy in turn was detected in 20 of 179 cases (11.2%). In order to classify subtypes of AML, we used a large panel of monoclonal antibodies, obtaining the following results: AML M0, 02 (1.1%) AML M1, 40 (22.3) AML M2, 60 (33.5) AML M3, 22 (12.3%) AML M4, 10 (5.6) AML M5, 13 (7.3%) AML M6 06 (3.4%) and AML M7 01 (0.6%). We observed some cases with aberrant expression of some antigens such as CD7, CD4, CD19, CD3, CD5 and TdT, CD 7 was present in 30 (16.8%), CD4 in 5 (2.8%), the CD 3 in 5 (2.8%), the CD19 in 3 (1.7%), the CD5 in 3 (1.7%) and TDT was in 7 (3.9%) cases of AML .the CD8 and CD79a was present in only a 1 case.
publishDate 2010
dc.date.issued.fl_str_mv 2010-02-24
dc.date.available.fl_str_mv 2012-05-21
2014-12-17T14:16:28Z
dc.date.accessioned.fl_str_mv 2014-12-17T14:16:28Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.citation.fl_str_mv VASCONCELOS, Roberto Chaves de. Avaliação dos marcadores celulares por citometria de fluxo nos portadores de leucemia mieloide aguda atendidos no Hemocentro do Rio Grande do Norte-Hemonorte. 2010. 121 f. Dissertação (Mestrado em Bioanálises e Medicamentos) - Universidade Federal do Rio Grande do Norte, Natal, 2010.
dc.identifier.uri.fl_str_mv https://repositorio.ufrn.br/jspui/handle/123456789/13464
identifier_str_mv VASCONCELOS, Roberto Chaves de. Avaliação dos marcadores celulares por citometria de fluxo nos portadores de leucemia mieloide aguda atendidos no Hemocentro do Rio Grande do Norte-Hemonorte. 2010. 121 f. Dissertação (Mestrado em Bioanálises e Medicamentos) - Universidade Federal do Rio Grande do Norte, Natal, 2010.
url https://repositorio.ufrn.br/jspui/handle/123456789/13464
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal do Rio Grande do Norte
dc.publisher.program.fl_str_mv Programa de Pós-Graduação em Ciências Farmacêuticas
dc.publisher.initials.fl_str_mv UFRN
dc.publisher.country.fl_str_mv BR
dc.publisher.department.fl_str_mv Bioanálises e Medicamentos
publisher.none.fl_str_mv Universidade Federal do Rio Grande do Norte
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRN
instname:Universidade Federal do Rio Grande do Norte (UFRN)
instacron:UFRN
instname_str Universidade Federal do Rio Grande do Norte (UFRN)
instacron_str UFRN
institution UFRN
reponame_str Repositório Institucional da UFRN
collection Repositório Institucional da UFRN
bitstream.url.fl_str_mv https://repositorio.ufrn.br/bitstream/123456789/13464/1/AvaliacaoMarcadoresCelulares_Vasconcelos_2010.pdf
https://repositorio.ufrn.br/bitstream/123456789/13464/6/RobertoCV_DISSERT.pdf.txt
https://repositorio.ufrn.br/bitstream/123456789/13464/8/AvaliacaoMarcadoresCelulares_Vasconcelos_2010.pdf.txt
https://repositorio.ufrn.br/bitstream/123456789/13464/7/RobertoCV_DISSERT.pdf.jpg
https://repositorio.ufrn.br/bitstream/123456789/13464/9/AvaliacaoMarcadoresCelulares_Vasconcelos_2010.pdf.jpg
bitstream.checksum.fl_str_mv a5ed04f6ae5794f328192fe513bdf03f
eb75e5e0b0b579d56e81d3bf30484dc7
ac68c063005584c312af018ad008b4e4
2e1e190227428bd5c170cab067e82d11
749abb9c20f803dc5218c4df1072179b
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN)
repository.mail.fl_str_mv
_version_ 1796767102583963648